Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May 31;12(5):e0177882.
doi: 10.1371/journal.pone.0177882. eCollection 2017.

Screening test for neutralizing antibodies against yellow fever virus, based on a flavivirus pseudotype

Séverine Mercier-Delarue  1 , Christine Durier  2 , Nathalie Colin de Verdière  3 , Jean-Dominique Poveda  4 , Vincent Meiffrédy  2 , Maria Dolores Fernandez Garcia  5 , Stéphane Lastère  6 , Raymond Césaire  7 , Jean-Claude Manuggera  8 , Jean-Michel Molina  3 , Ali Amara  5 , François Simon  1
Affiliations

Screening test for neutralizing antibodies against yellow fever virus, based on a flavivirus pseudotype

Séverine Mercier-Delarue et al. PLoS One. .

Abstract

Given the possibility of yellow fever virus reintroduction in epidemiologically receptive geographic areas, the risk of vaccine supply disruption is a serious issue. New strategies to reduce the doses of injected vaccines should be evaluated very carefully in terms of immunogenicity. The plaque reduction test for the determination of neutralizing antibodies (PRNT) is particularly time-consuming and requires the use of a confinement laboratory. We have developed a new test based on the use of a non-infectious pseudovirus (WN/YF17D). The presence of a reporter gene allows sensitive determination of neutralizing antibodies by flow cytometry. This WN/YF17D test was as sensitive as PRNT for the follow-up of yellow fever vaccinees. Both tests lacked specificity with sera from patients hospitalized for acute Dengue virus infection. Conversely, both assays were strictly negative in adults never exposed to flavivirus infection or vaccination, and in patients sampled some time after acute Dengue infection. This WN/YF17D test will be particularly useful for large epidemiological studies and for screening for neutralizing antibodies against yellow fever virus.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: Cerba laboratories just provide the financial support as Dr. Poveda’s salaries and have no role in the study design and analysis or decision to publish. This commercial affiliation does not alter our adherence to PLOS ONE policies on sharing data and materials.

Figures

Fig 1
Fig 1. NOVAA-test results: Percentage of neutralization with 20 sera from patients with PRNT titres ranging from 10 to 80.
Four complementary sera with a previous PRNT results of 40 were diluted 1:4 in order to surround the cut-off for neutralizing antibody detection by PRNT.
See this image and copyright information in PMC

References

    1. Barrett ADT. Yellow Fever in Angola and Beyond—The Problem of Vaccine Supply and Demand. N Engl J Med. 2016;375: 301–303. doi: 10.1056/NEJMp1606997 - DOI - PubMed
    1. Monath TP, Vasconcelos PFC. Yellow fever. J Clin Virol Off Publ Pan Am Soc Clin Virol. 2015;64: 160–173. - PubMed
    1. Frierson JG. The yellow fever vaccine: a history. Yale J Biol Med. 2010;83: 77–85. - PMC - PubMed
    1. Who. Vaccines and vaccination against yellow fever: WHO Position Paper, June 2013—recommendations. Vaccine. 2015;33: 76–77. doi: 10.1016/j.vaccine.2014.05.040 - DOI - PubMed
    1. Gotuzzo E, Yactayo S, Córdova E. Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am J Trop Med Hyg. 2013;89: 434–444. doi: 10.4269/ajtmh.13-0264 - DOI - PMC - PubMed